U.S. markets closed
  • S&P Futures

    4,512.75
    +1.50 (+0.03%)
     
  • Dow Futures

    35,359.00
    +36.00 (+0.10%)
     
  • Nasdaq Futures

    15,381.50
    -17.00 (-0.11%)
     
  • Russell 2000 Futures

    2,274.60
    +1.80 (+0.08%)
     
  • Crude Oil

    83.02
    +0.06 (+0.07%)
     
  • Gold

    1,768.20
    -2.30 (-0.13%)
     
  • Silver

    23.66
    -0.23 (-0.95%)
     
  • EUR/USD

    1.1637
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • Vix

    15.70
    -0.61 (-3.74%)
     
  • GBP/USD

    1.3793
    -0.0000 (-0.00%)
     
  • USD/JPY

    114.5660
    +0.2060 (+0.18%)
     
  • BTC-USD

    64,006.66
    +2,173.75 (+3.52%)
     
  • CMC Crypto 200

    1,483.12
    +19.76 (+1.35%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,466.40
    +250.88 (+0.86%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, EBS and PRVB

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 14, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Class Period: June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline: June 18, 2021

Acadia Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ACAD: http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=16877&from=1

Emergent Biosolutions Inc. (NYSE:EBS)
Class Period: April 24, 2020 - April 16, 2021
Lead Plaintiff Deadline: June 18, 2021

The EBS lawsuit alleges that throughout the class period, Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in EBS: http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=16877&from=1

Provention Bio, Inc. (NASDAQ:PRVB)
Class Period: November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline: July 20, 2021

According to the complaint, Provention Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in PRVB: https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=16877&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/651729/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ACAD-EBS-and-PRVB